Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values
Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two f...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 65; no. 4; pp. 1145 - 1155 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health, Inc
01.04.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 0270-9139 1527-3350 1527-3350 |
DOI | 10.1002/hep.28843 |
Cover
Abstract | Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132‐298, middle 299‐338, higher 339‐400 dB/m). Among patients with F0‐F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3‐F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848‐0.982; 0.830, 0.753‐0.908; 0.806, 0.723‐0.890). As a consequence, in subjects with F0‐F2 fibrosis, the rates of false‐positive LSM results for F3‐F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. Conclusions: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145‐1155). |
---|---|
AbstractList | Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132-298, middle 299-338, higher 339-400 dB/m). Among patients with F0-F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3-F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848-0.982; 0.830, 0.753-0.908; 0.806, 0.723-0.890). As a consequence, in subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values.Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132-298, middle 299-338, higher 339-400 dB/m). Among patients with F0-F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3-F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848-0.982; 0.830, 0.753-0.908; 0.806, 0.723-0.890). As a consequence, in subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values.In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145-1155).CONCLUSIONSIn patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145-1155). Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132‐298, middle 299‐338, higher 339‐400 dB/m). Among patients with F0‐F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3‐F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848‐0.982; 0.830, 0.753‐0.908; 0.806, 0.723‐0.890). As a consequence, in subjects with F0‐F2 fibrosis, the rates of false‐positive LSM results for F3‐F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. Conclusions: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145‐1155). Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132-298, middle 299-338, higher 339-400 dB/m). Among patients with F0-F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3-F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848-0.982; 0.830, 0.753-0.908; 0.806, 0.723-0.890). As a consequence, in subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145-1155). Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132‐298, middle 299‐338, higher 339‐400 dB/m). Among patients with F0‐F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3‐F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848‐0.982; 0.830, 0.753‐0.908; 0.806, 0.723‐0.890). As a consequence, in subjects with F0‐F2 fibrosis, the rates of false‐positive LSM results for F3‐F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. Conclusions: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (H epatology 2017;65:1145‐1155). |
Author | de Ledinghen, Victor Merrouche, Wassil Wong, Vincent Wai‐Sun Cammà, Calogero Chan, Henry Lik‐Yuen Marra, Fabio Barbara, Marco Petta, Salvatore Vergniol, Julien Di Marco, Vito Chan, Anthony Wing‐Hung Wong, Grace Lai‐Hung Arena, Umberto Hiriart, Jean‐Baptiste Craxì, Antonio Le‐Bail, Brigitte |
Author_xml | – sequence: 1 givenname: Salvatore surname: Petta fullname: Petta, Salvatore email: petsa@inwind.it, salvatore.petta@unipa.it organization: University of Palermo – sequence: 2 givenname: Vincent Wai‐Sun surname: Wong fullname: Wong, Vincent Wai‐Sun organization: The Chinese University of Hong Kong – sequence: 3 givenname: Calogero surname: Cammà fullname: Cammà, Calogero organization: University of Palermo – sequence: 4 givenname: Jean‐Baptiste surname: Hiriart fullname: Hiriart, Jean‐Baptiste organization: Bordeaux University Hospital – sequence: 5 givenname: Grace Lai‐Hung surname: Wong fullname: Wong, Grace Lai‐Hung organization: The Chinese University of Hong Kong – sequence: 6 givenname: Fabio surname: Marra fullname: Marra, Fabio organization: Università degli Studi di Firenze – sequence: 7 givenname: Julien surname: Vergniol fullname: Vergniol, Julien organization: Bordeaux University Hospital – sequence: 8 givenname: Anthony Wing‐Hung surname: Chan fullname: Chan, Anthony Wing‐Hung organization: The Chinese University of Hong Kong – sequence: 9 givenname: Vito surname: Di Marco fullname: Di Marco, Vito organization: University of Palermo – sequence: 10 givenname: Wassil surname: Merrouche fullname: Merrouche, Wassil organization: Bordeaux University Hospital – sequence: 11 givenname: Henry Lik‐Yuen surname: Chan fullname: Chan, Henry Lik‐Yuen organization: The Chinese University of Hong Kong – sequence: 12 givenname: Marco surname: Barbara fullname: Barbara, Marco organization: University of Palermo – sequence: 13 givenname: Brigitte surname: Le‐Bail fullname: Le‐Bail, Brigitte organization: Bordeaux University Hospital – sequence: 14 givenname: Umberto surname: Arena fullname: Arena, Umberto organization: Università degli Studi di Firenze – sequence: 15 givenname: Antonio surname: Craxì fullname: Craxì, Antonio organization: University of Palermo – sequence: 16 givenname: Victor surname: de Ledinghen fullname: de Ledinghen, Victor organization: Bordeaux University Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27639088$$D View this record in MEDLINE/PubMed |
BookMark | eNqNksFu1DAQhi1URLcLB14AWeICh7R2nMT2EVWFVqoEBzhHjjNmXTl2sJ2t9tH6dri7Ww6VQJw8Gn3_718zc4ZOfPCA0FtKzikh9cUG5vNaiIa9QCva1rxirCUnaEVqTipJmTxFZyndEUJkU4tX6LTmHZNEiBV6uJnmGLYw4uJp_VYluwU8RxitzjZ4HAx2pRWxsUMMySY87I6dlK0xHlLCE6i0RJjAZ2w9nlW2pUz43ubNo7FyOmyCsxoblfOTfrSp6AArrcPis_U_sQkR6-BzDM6VTAUGv6h9kFlFNUEuuq1yC6TX6KVRLsGb47tGPz5ffb-8rm6_frm5_HRbaSY6VmnFKR215pJx1pmmMURCbfjAu0Z1ULfjMEihxoFpPnbNSDgMTVPTdmQA0mi2Rh8OvmVOv8q_uZ9s0uCc8hCW1FMhhGw7WvP_QFvJGesaUtD3z9C7sMQyqL0hoZy3JfEavTtSyzDB2M_RTiru-qf9FeDjAdBlNymC-YNQ0j_eRl9uo9_fRmEvnrHa5v1sc1TW_Utxbx3s_m7dX199Oyh-A95A0CA |
CODEN | HPTLD9 |
CitedBy_id | crossref_primary_10_1097_MCG_0000000000001380 crossref_primary_10_3748_wjg_v30_i4_290 crossref_primary_10_1007_s10620_017_4592_0 crossref_primary_10_1016_j_cgh_2020_04_018 crossref_primary_10_1002_oby_24033 crossref_primary_10_1007_s00535_020_01686_8 crossref_primary_10_18632_aging_103522 crossref_primary_10_3390_nu11123070 crossref_primary_10_1016_j_clnu_2023_03_021 crossref_primary_10_1053_j_gastro_2018_12_036 crossref_primary_10_1111_apt_18215 crossref_primary_10_1111_apt_18176 crossref_primary_10_1016_j_cgh_2024_10_014 crossref_primary_10_1007_s00535_022_01932_1 crossref_primary_10_1016_j_jhep_2017_11_028 crossref_primary_10_1177_2050640619854671 crossref_primary_10_1186_s13244_024_01857_8 crossref_primary_10_1002_ueg2_12280 crossref_primary_10_1371_journal_pone_0182202 crossref_primary_10_1016_j_dld_2021_06_015 crossref_primary_10_1155_2021_8859338 crossref_primary_10_1016_j_ultrasmedbio_2024_01_002 crossref_primary_10_1371_journal_pgph_0003572 crossref_primary_10_1136_bmjgast_2017_000158 crossref_primary_10_1186_s12876_021_01974_4 crossref_primary_10_3389_fmed_2022_862879 crossref_primary_10_3390_biomedicines11082108 crossref_primary_10_1016_j_actbio_2021_01_019 crossref_primary_10_1111_apt_14529 crossref_primary_10_5005_jp_journals_10018_1425 crossref_primary_10_1111_apt_15298 crossref_primary_10_1016_j_ultrasmedbio_2020_11_015 crossref_primary_10_1097_MD_0000000000010462 crossref_primary_10_2147_HMER_S265473 crossref_primary_10_1007_s10620_020_06748_8 crossref_primary_10_1097_RLI_0000000000000529 crossref_primary_10_1155_2020_4217512 crossref_primary_10_3389_fphys_2022_1046497 crossref_primary_10_7759_cureus_65089 crossref_primary_10_14309_ajg_0000000000000153 crossref_primary_10_1186_s43066_020_00044_w crossref_primary_10_1371_journal_pone_0221548 crossref_primary_10_1002_mp_15484 crossref_primary_10_1016_j_clinre_2021_101769 crossref_primary_10_3748_wjg_v24_i11_1250 crossref_primary_10_1111_liv_14001 crossref_primary_10_33590_emj_10310531 crossref_primary_10_1177_2050640619865133 crossref_primary_10_1038_nrgastro_2018_10 crossref_primary_10_1097_QAI_0000000000001936 crossref_primary_10_3748_wjg_v27_i1_80 crossref_primary_10_1111_ijcp_13635 crossref_primary_10_31083_j_rcm2203082 crossref_primary_10_1177_2050640619900820 crossref_primary_10_3350_cmh_2024_0506 crossref_primary_10_1155_grp_6722810 crossref_primary_10_1111_jgh_14963 crossref_primary_10_1186_s13063_020_4068_y crossref_primary_10_1016_j_ultrasmedbio_2018_07_008 crossref_primary_10_1016_j_numecd_2021_04_028 crossref_primary_10_1016_j_ultrasmedbio_2024_03_013 crossref_primary_10_1016_j_clinre_2022_101957 crossref_primary_10_1016_j_ultrasmedbio_2024_03_014 crossref_primary_10_1097_MEG_0000000000001736 crossref_primary_10_1016_j_clinre_2019_03_009 crossref_primary_10_4166_kjg_2024_103 crossref_primary_10_1016_j_clnu_2022_07_003 crossref_primary_10_1016_j_eclinm_2022_101547 crossref_primary_10_1111_liv_13602 crossref_primary_10_3389_fendo_2023_1144838 crossref_primary_10_14218_JCTH_2017_00009 crossref_primary_10_4093_dmj_2020_0137 crossref_primary_10_1080_00952990_2020_1833211 crossref_primary_10_1016_j_clinre_2018_10_017 crossref_primary_10_1111_jgh_14311 crossref_primary_10_1111_apt_18061 crossref_primary_10_2214_AJR_22_27656 crossref_primary_10_3390_metabo14010052 crossref_primary_10_3390_diagnostics13071236 crossref_primary_10_1007_s11695_020_04513_4 crossref_primary_10_1136_postgradmedj_2018_136111 crossref_primary_10_3390_biomedicines8090298 crossref_primary_10_1177_2050640618792819 crossref_primary_10_1016_S2468_1253_18_30077_3 crossref_primary_10_1007_s11695_020_05002_4 crossref_primary_10_1016_j_medcli_2019_01_030 crossref_primary_10_1097_HEP_0000000000000852 crossref_primary_10_3389_fimmu_2020_634409 crossref_primary_10_1007_s10278_021_00521_7 crossref_primary_10_2174_1381612826666200521133307 crossref_primary_10_1007_s10396_021_01106_1 crossref_primary_10_1016_j_medcle_2019_06_010 crossref_primary_10_1007_s12072_022_10368_x crossref_primary_10_1097_MEG_0000000000000919 crossref_primary_10_1002_hep4_1719 crossref_primary_10_1111_apt_14219 crossref_primary_10_3748_wjg_v23_i36_6571 crossref_primary_10_1155_2019_2013674 crossref_primary_10_5500_wjt_v11_i3_37 crossref_primary_10_1007_s40519_021_01287_1 crossref_primary_10_1016_j_jhep_2017_12_029 crossref_primary_10_1016_j_jhep_2021_04_044 crossref_primary_10_1016_j_actbio_2018_10_010 crossref_primary_10_33590_emjhepatol_10311541 crossref_primary_10_3748_wjg_v25_i33_4959 crossref_primary_10_1080_17474124_2019_1621164 crossref_primary_10_1136_gutjnl_2021_324243 crossref_primary_10_14218_JCTH_2021_00188 crossref_primary_10_1038_s41598_021_93294_6 crossref_primary_10_1371_journal_pone_0224506 crossref_primary_10_22516_25007440_1156 crossref_primary_10_1111_liv_13549 crossref_primary_10_3389_fped_2023_1194641 crossref_primary_10_1016_j_dld_2021_04_029 crossref_primary_10_1097_SGA_0000000000000461 crossref_primary_10_14218_JCTH_2018_00048 crossref_primary_10_1111_hepr_13442 crossref_primary_10_1186_s12876_019_0961_9 crossref_primary_10_1055_a_1010_6052 crossref_primary_10_3138_canlivj_2020_0040 crossref_primary_10_3350_cmh_2019_0001n crossref_primary_10_1002_hep4_1435 crossref_primary_10_1007_s11695_019_04192_w crossref_primary_10_1159_000526503 crossref_primary_10_33590_emj_10314271 crossref_primary_10_1016_j_cgh_2020_06_045 crossref_primary_10_1097_MEG_0000000000002412 crossref_primary_10_1080_17474124_2018_1415756 crossref_primary_10_1016_j_cld_2017_08_004 crossref_primary_10_1155_2018_8490242 crossref_primary_10_1016_j_banm_2023_03_014 crossref_primary_10_1111_1751_2980_12685 crossref_primary_10_1007_s11901_017_0368_4 crossref_primary_10_1016_j_metop_2021_100158 crossref_primary_10_1088_1361_6560_abd593 crossref_primary_10_1016_j_jhep_2021_05_025 crossref_primary_10_18525_cu_2024_9_2_70 crossref_primary_10_1111_hepr_13831 crossref_primary_10_1111_liv_14325 crossref_primary_10_1007_s10620_020_06269_4 crossref_primary_10_1111_liv_14167 crossref_primary_10_1155_2021_6662760 crossref_primary_10_1016_j_cgh_2018_04_062 crossref_primary_10_1002_hep4_1467 crossref_primary_10_1016_j_clinre_2023_102183 crossref_primary_10_1111_1751_2980_12830 crossref_primary_10_1080_17512433_2017_1299573 crossref_primary_10_1055_a_2015_5693 crossref_primary_10_1002_hep_30672 crossref_primary_10_1016_j_jhepr_2020_100067 crossref_primary_10_1053_j_gastro_2019_01_042 crossref_primary_10_1007_s12072_017_9795_0 crossref_primary_10_1097_HEP_0000000000000843 crossref_primary_10_1002_hep_29067 crossref_primary_10_1371_journal_pone_0200656 crossref_primary_10_1016_j_aohep_2020_01_003 crossref_primary_10_1002_hep_29065 crossref_primary_10_1007_s10620_019_05702_7 crossref_primary_10_1016_j_ultrasmedbio_2022_03_019 crossref_primary_10_1111_hepr_13821 crossref_primary_10_14366_usg_19034 crossref_primary_10_1016_j_cgh_2017_09_044 crossref_primary_10_3390_cancers12102778 crossref_primary_10_1016_j_jhep_2017_05_011 crossref_primary_10_1136_gutjnl_2018_317334 crossref_primary_10_1016_j_deman_2023_100161 crossref_primary_10_14366_usg_20147 crossref_primary_10_1111_jvh_12715 crossref_primary_10_1111_apt_14584 crossref_primary_10_1155_2019_2151302 crossref_primary_10_3390_jcm10081569 crossref_primary_10_1016_j_cgh_2017_12_018 crossref_primary_10_1159_000478944 |
Cites_doi | 10.1016/j.jhep.2015.11.004 10.1016/j.cgh.2014.12.014 10.1053/j.gastro.2015.11.048 10.1002/hep.27368 10.1002/hep.27844 10.1111/j.1365-2036.2011.04668.x 10.1016/j.jhep.2015.10.016 10.1016/j.cgh.2012.09.025 10.1038/ajg.2012.331 10.1016/S0168-8278(03)00191-0 10.1053/j.gastro.2014.11.039 10.1097/MEG.0b013e3282f51992 10.1111/liv.12584 10.1111/jgh.13219 10.1002/hep.24694 10.1016/j.jhep.2013.08.011 10.1002/hep.23312 10.1002/hep.27362 10.1053/j.gastro.2015.04.043 10.1053/j.gastro.2005.03.084 10.2174/1381612811319290004 10.1111/liv.12809 10.1002/hep.24624 10.1016/j.jhep.2011.10.017 10.1097/MEG.0b013e32835f4c3d 10.1002/hep.25993 10.1002/hep.21496 |
ContentType | Journal Article |
Copyright | 2016 by the American Association for the Study of Liver Diseases. 2017 by the American Association for the Study of Liver Diseases. |
Copyright_xml | – notice: 2016 by the American Association for the Study of Liver Diseases. – notice: 2017 by the American Association for the Study of Liver Diseases. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
DOI | 10.1002/hep.28843 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1527-3350 |
EndPage | 1155 |
ExternalDocumentID | 4321099633 27639088 10_1002_hep_28843 HEP28843 |
Genre | article Journal Article Comparative Study |
GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABJNI ACZKN ADSXY AEFGJ AFNMH AGQPQ AGXDD AHQVU AIDQK AIDYY AIQQE CITATION MEWTI WXSBR ACIJW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3863-ca711dcc793736f44f09e2f7b764a6e25dbb98adb3c7d64d07eb44215d3ee9fc3 |
IEDL.DBID | DR2 |
ISSN | 0270-9139 1527-3350 |
IngestDate | Thu Sep 04 19:01:36 EDT 2025 Fri Sep 05 14:53:08 EDT 2025 Wed Aug 13 11:33:22 EDT 2025 Wed Feb 19 02:41:00 EST 2025 Wed Oct 01 04:13:19 EDT 2025 Thu Apr 24 23:09:10 EDT 2025 Wed Jan 22 16:15:13 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | 2016 by the American Association for the Study of Liver Diseases. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3863-ca711dcc793736f44f09e2f7b764a6e25dbb98adb3c7d64d07eb44215d3ee9fc3 |
Notes | Potential conflict of interest: Dr. G. Wong, Dr. V. Wong, Dr. H. Chan received lecture fees from Echosens. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
PMID | 27639088 |
PQID | 1880177579 |
PQPubID | 996352 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1888956127 proquest_miscellaneous_1859733640 proquest_journals_1880177579 pubmed_primary_27639088 crossref_primary_10_1002_hep_28843 crossref_citationtrail_10_1002_hep_28843 wiley_primary_10_1002_hep_28843_HEP28843 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2017 2017-04-00 20170401 |
PublicationDateYYYYMMDD | 2017-04-01 |
PublicationDate_xml | – month: 04 year: 2017 text: April 2017 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Hepatology (Baltimore, Md.) |
PublicationTitleAlternate | Hepatology |
PublicationYear | 2017 |
Publisher | Wolters Kluwer Health, Inc |
Publisher_xml | – name: Wolters Kluwer Health, Inc |
References | 2015; 35 2015; 13 2013; 25 2015; 148 2015; 149 2000; 23 2005; 411 2016; 31 2011; 33 2003; 39 2012; 56 2014; 60 2012; 55 2012; 107 2013; 19 2013; 11 2015; 62 2013; 57 2015; 61 2015; 64 2015; 63 2005; 128 2016; 64 2008; 20 2007; 45 2010; 51 2016; 150 (hep28843-bib-0029-20241017) 2008; 20 (hep28843-bib-0011-20241017) 2015; 63 (hep28843-bib-0014-20241017) 2012; 55 (hep28843-bib-0012-20241017) 2015; 62 (hep28843-bib-0019-20241017) 2003; 39 (hep28843-bib-0028-20241017) 2015; 13 (hep28843-bib-0023-20241017) 2015; 35 (hep28843-bib-0015-20241017) 2011; 33 (hep28843-bib-0017-20241017) 2000; 23 (hep28843-bib-0004-20241017) 2015; 61 (hep28843-bib-0031-20241017) 2016; 64 (hep28843-bib-0009-20241017) 2012; 107 (hep28843-bib-0013-20241017) 2013; 11 (hep28843-bib-0006-20241017) 2005; 128 (hep28843-bib-0021-20241017) 2015; 35 (hep28843-bib-0008-20241017) 2016; 64 (hep28843-bib-0005-20241017) 2015; 149 (hep28843-bib-0007-20241017) 2013; 19 (hep28843-bib-0016-20241017) 2016; 31 (hep28843-bib-0020-20241017) 2005; 411 (hep28843-bib-0010-20241017) 2010; 51 (hep28843-bib-0001-20241017) 2015; 64 (hep28843-bib-0024-20241017) 2014; 60 (hep28843-bib-0025-20241017) 2016; 150 (hep28843-bib-0022-20241017) 2007; 45 (hep28843-bib-0003-20241017) 2015; 148 (hep28843-bib-0030-20241017) 2013; 25 (hep28843-bib-0018-20241017) 2013; 57 (hep28843-bib-0026-20241017) 2012; 55 (hep28843-bib-0002-20241017) 2014; 60 (hep28843-bib-0027-20241017) 2012; 56 28103627 - Hepatology. 2017 Jun;65(6):2128 28103641 - Hepatology. 2017 Jun;65(6):2126-2128 |
References_xml | – volume: 11 start-page: 295 year: 2013 end-page: 302 article-title: Association between anthropometric parameters and measurements of liver stiffness by transient elastography publication-title: Clin Gastroenterol Hepatol – volume: 56 start-page: 833 year: 2012 end-page: 839 article-title: Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan publication-title: J Hepatol – volume: 411 start-page: 313 year: 2005 end-page: 321 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology – volume: 55 start-page: 584 year: 2012 end-page: 593 article-title: Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population‐based study from a developing country publication-title: Hepatology – volume: 149 start-page: 389 year: 2015 end-page: 397 article-title: Liver fibrosis, but no other histologic features, associates with long‐term outcomes of patients with nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 60 start-page: 1920 year: 2014 end-page: 1928 article-title: Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study publication-title: Hepatology – volume: 148 start-page: 547 year: 2015 end-page: 555 article-title: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States publication-title: Gastroenterology – volume: 55 start-page: 199 year: 2012 end-page: 208 article-title: Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients publication-title: Hepatology – volume: 45 start-page: 846 year: 2007 end-page: 854 article-title: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD publication-title: Hepatology – volume: 13 start-page: 772 year: 2015 end-page: 9 article-title: Accuracy of FibroScan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study publication-title: Clin Gastroenterol Hepatol – volume: 150 start-page: 626 year: 2016 end-page: 637 article-title: Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography publication-title: Gastroenterology – volume: 63 start-page: 1817 year: 2015 end-page: 1827 article-title: Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan and ARFI with liver biopsy publication-title: Hepatology – volume: 23 start-page: S4 issue: Suppl. year: 2000 end-page: S19 article-title: Clinical practice recommendations 2000 publication-title: Diabetes Care – volume: 35 start-page: 2392 year: 2015 end-page: 2400 article-title: Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease publication-title: Liver Int – volume: 35 start-page: 1566 year: 2015 end-page: 1573 article-title: The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease publication-title: Liver Int – volume: 19 start-page: 5193 year: 2013 end-page: 5218 article-title: Non invasive indexes for the assessment of patients with non‐alcoholic fatty liver disease publication-title: Curr Pharm Des – volume: 107 start-page: 1862 year: 2012 end-page: 1871 article-title: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease publication-title: Am J Gastroenterol – volume: 25 start-page: 905 year: 2013 end-page: 911 article-title: Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography publication-title: Eur J Gastroenterol Hepatol – volume: 39 start-page: 239 year: 2003 end-page: 244 article-title: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease publication-title: J Hepatol – volume: 60 start-page: 110 year: 2014 end-page: 117 article-title: Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team publication-title: J Hepatol – volume: 33 start-page: 1350 year: 2011 end-page: 1360 article-title: Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index publication-title: Aliment Pharmacol Ther – volume: 20 start-page: 693 year: 2008 end-page: 701 article-title: Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography publication-title: Eur J Gastroenterol Hepatol – volume: 62 start-page: 1101 year: 2015 end-page: 1110 article-title: The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease publication-title: Hepatology – volume: 128 start-page: 1898 year: 2005 end-page: 1906 article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 64 start-page: 73 year: 2015 end-page: 84 article-title: Global epidemiology of non‐alcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence and outcomes publication-title: Hepatology – volume: 51 start-page: 454 year: 2010 end-page: 462 article-title: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease publication-title: Hepatology – volume: 57 start-page: 1182 year: 2013 end-page: 1191 article-title: Determination of reliability criteria for liver stiffness evaluation by transient elastography publication-title: Hepatology – volume: 61 start-page: 1547 year: 2015 end-page: 1554 article-title: Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up publication-title: Hepatology – volume: 64 start-page: 682 year: 2016 end-page: 690 article-title: MERTK rs4374383 polymorphism affects the severity of fibrosis in non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 31 start-page: 848 year: 2016 end-page: 855 article-title: Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease publication-title: J Gastroenterol Hepatol – volume: 64 start-page: 1388 year: 2016 end-page: 1402 article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 64 start-page: 1388 year: 2016 ident: hep28843-bib-0008-20241017 article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2015.11.004 – volume: 411 start-page: 313 year: 2005 ident: hep28843-bib-0020-20241017 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology – volume: 13 start-page: 772 year: 2015 ident: hep28843-bib-0028-20241017 article-title: Accuracy of FibroScan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.12.014 – volume: 64 start-page: 73 year: 2015 ident: hep28843-bib-0001-20241017 article-title: Global epidemiology of non‐alcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence and outcomes publication-title: Hepatology – volume: 150 start-page: 626 year: 2016 ident: hep28843-bib-0025-20241017 article-title: Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.11.048 – volume: 61 start-page: 1547 year: 2015 ident: hep28843-bib-0004-20241017 article-title: Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up publication-title: Hepatology doi: 10.1002/hep.27368 – volume: 62 start-page: 1101 year: 2015 ident: hep28843-bib-0012-20241017 article-title: The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.27844 – volume: 33 start-page: 1350 year: 2011 ident: hep28843-bib-0015-20241017 article-title: Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2011.04668.x – volume: 23 start-page: S4 issue: Suppl. year: 2000 ident: hep28843-bib-0017-20241017 article-title: Clinical practice recommendations 2000 publication-title: Diabetes Care – volume: 64 start-page: 682 year: 2016 ident: hep28843-bib-0031-20241017 article-title: MERTK rs4374383 polymorphism affects the severity of fibrosis in non‐alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2015.10.016 – volume: 11 start-page: 295 year: 2013 ident: hep28843-bib-0013-20241017 article-title: Association between anthropometric parameters and measurements of liver stiffness by transient elastography publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2012.09.025 – volume: 107 start-page: 1862 year: 2012 ident: hep28843-bib-0009-20241017 article-title: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease publication-title: Am J Gastroenterol doi: 10.1038/ajg.2012.331 – volume: 39 start-page: 239 year: 2003 ident: hep28843-bib-0019-20241017 article-title: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease publication-title: J Hepatol doi: 10.1016/S0168-8278(03)00191-0 – volume: 148 start-page: 547 year: 2015 ident: hep28843-bib-0003-20241017 article-title: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.11.039 – volume: 20 start-page: 693 year: 2008 ident: hep28843-bib-0029-20241017 article-title: Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e3282f51992 – volume: 35 start-page: 1566 year: 2015 ident: hep28843-bib-0023-20241017 article-title: The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease publication-title: Liver Int doi: 10.1111/liv.12584 – volume: 31 start-page: 848 year: 2016 ident: hep28843-bib-0016-20241017 article-title: Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13219 – volume: 63 start-page: 1817 year: 2015 ident: hep28843-bib-0011-20241017 article-title: Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan and ARFI with liver biopsy publication-title: Hepatology – volume: 55 start-page: 584 year: 2012 ident: hep28843-bib-0014-20241017 article-title: Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population‐based study from a developing country publication-title: Hepatology doi: 10.1002/hep.24694 – volume: 60 start-page: 110 year: 2014 ident: hep28843-bib-0002-20241017 article-title: Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team publication-title: J Hepatol doi: 10.1016/j.jhep.2013.08.011 – volume: 51 start-page: 454 year: 2010 ident: hep28843-bib-0010-20241017 article-title: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.23312 – volume: 60 start-page: 1920 year: 2014 ident: hep28843-bib-0024-20241017 article-title: Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study publication-title: Hepatology doi: 10.1002/hep.27362 – volume: 149 start-page: 389 year: 2015 ident: hep28843-bib-0005-20241017 article-title: Liver fibrosis, but no other histologic features, associates with long‐term outcomes of patients with nonalcoholic fatty liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.04.043 – volume: 128 start-page: 1898 year: 2005 ident: hep28843-bib-0006-20241017 article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2005.03.084 – volume: 19 start-page: 5193 year: 2013 ident: hep28843-bib-0007-20241017 article-title: Non invasive indexes for the assessment of patients with non‐alcoholic fatty liver disease publication-title: Curr Pharm Des doi: 10.2174/1381612811319290004 – volume: 35 start-page: 2392 year: 2015 ident: hep28843-bib-0021-20241017 article-title: Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease publication-title: Liver Int doi: 10.1111/liv.12809 – volume: 55 start-page: 199 year: 2012 ident: hep28843-bib-0026-20241017 article-title: Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients publication-title: Hepatology doi: 10.1002/hep.24624 – volume: 56 start-page: 833 year: 2012 ident: hep28843-bib-0027-20241017 article-title: Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan® publication-title: J Hepatol doi: 10.1016/j.jhep.2011.10.017 – volume: 25 start-page: 905 year: 2013 ident: hep28843-bib-0030-20241017 article-title: Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32835f4c3d – volume: 57 start-page: 1182 year: 2013 ident: hep28843-bib-0018-20241017 article-title: Determination of reliability criteria for liver stiffness evaluation by transient elastography publication-title: Hepatology doi: 10.1002/hep.25993 – volume: 45 start-page: 846 year: 2007 ident: hep28843-bib-0022-20241017 article-title: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD publication-title: Hepatology doi: 10.1002/hep.21496 – reference: 28103641 - Hepatology. 2017 Jun;65(6):2126-2128 – reference: 28103627 - Hepatology. 2017 Jun;65(6):2128 |
SSID | ssj0009428 |
Score | 2.5904388 |
Snippet | Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1145 |
SubjectTerms | Adult Age Factors Aged Analysis of Variance Biopsy, Needle Cohort Studies Elasticity Imaging Techniques - methods Elasticity Imaging Techniques - trends Female Hepatology Humans Immunohistochemistry Liver Cirrhosis - pathology Liver diseases Male Middle Aged Multivariate Analysis Non-alcoholic Fatty Liver Disease - pathology Predictive Value of Tests Quality Improvement Risk Assessment ROC Curve Sensitivity and Specificity Sex Factors |
Title | Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28843 https://www.ncbi.nlm.nih.gov/pubmed/27639088 https://www.proquest.com/docview/1880177579 https://www.proquest.com/docview/1859733640 https://www.proquest.com/docview/1888956127 |
Volume | 65 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1527-3350 dateEnd: 20241003 omitProxy: true ssIdentifier: ssj0009428 issn: 0270-9139 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0270-9139 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1527-3350 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009428 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_HPYgvfn-snhLFB1-61yZpkuKTyB2LcCLiwT0IJZ-43F53uXYF_c_878wkaZfzC_GtpJN2wmSSyczkNwi9cESUVlpRKCdpwYRvClVaW4TNWdVKKl4puOB88o4vTtnbs_psD70a78IkfIjJ4QaaEddrUHCl-8MdaOhnt5kTKRkgfVa0jiHaDzvoqIbFuqrh1FVCdLkZUYVKcjj1vLoX_WJgXrVX44ZzfBN9GllNeSbn8-2g5-bbTyiO_zmWW-hGNkTx6zRzbqM9191B105yqP0u-p7cDc7iDjy2XxTkuePNJRCAMPHa4xUkdWAffr3ulz3WX3NLWDa8hzUUX-xckHjZ4Yzi2mNw_8KHVarQuzTYq2EY--eoEVZTKQscbGuc0-pXgSdABe0SSjkG9PILyOrBgFzu-nvo9Pjo45tFkes8FIZKTgujRFVZYwCqj3LPmC8bR7zQgjPFHamt1o1UVlMjLGe2FE4zFmwVS51rvKH30X7g2D1E2HEXDkw0tEFf6WXJrWcNtaSUoQ-doZejxFuTQdChFseqTfDNpA2iaKMoZuj5RLpJyB-_IzoYp02blb9vAeKuEqIWzQw9m14HtYVYjOrcegs04SRHKWfl32ikhHvHRMzQgzQlJ05I2BcgRS0MKE6sP7PYLo7ex4dH_076GF0nYL7EDKUDtD9cbt2TYHwN-mnUsh8SGDEF |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o-lBQziwCVbr-21HYlLVVot0K0QaqVeUOT4IVZss6smiwT_jH9XT16r8hLiFjnjZKzx2OOZ8TcALz1T1GmnEuM1T4QKaWKoc0ncnM3YaCNHBi84T4_k5ES8Ox2fbsDr7i5Mgw_RO9xQM-r1GhUcHdI7a9TQz345ZFoLfgWuYnwO1fLNxzV4VCrqyqrx3EUxvpx2uEKU7fRdL-9Gv5iYly3Wess5uAWfOmabTJMvw1WVD-33n3Ac_3c0t-Fma4uS3Wby3IENX9yFa9M22n4PfjQeB-9IgU7brwZT3cnyHAlQnmQRyBzzOkiI_16Us5Lk39qWuHKEgMsoOVt7IcmsIC2Qa0nQA4wfNk2R3pklwVRV178NHBHTV7Mg0bwmbWb9PPKEwKBFA1ROEMD8DBN7CIKX-_I-nBzsH-9NkrbUQ2K5ljyxRo1GzlpE6-MyCBFo6llQuZLCSM_GLs9TbVzOrXJSOKp8LkQ0Vxz3Pg2WP4DNyLF_BMRLH89MPLZhXx00lS6IlDtGdezDB_CqE3lmWxx0LMcxzxoEZ5ZFUWS1KAbwoiddNuAfvyPa7uZN1up_mSHK3UipsUoH8Lx_HTUXwzGm8IsV0sTDHOdS0L_RaI1Xj5kawMNmTvacsLg1YJZaHFA9s_7MYjbZ_1A_PP530mdwfXI8PcwO3x6934IbDK2ZOmFpGzar85V_Em2xKn9aq9wF76o1IQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceFMWWjCIA5dsvbbXdsQJ0a6WR6sKUakHpMiJbbFim101WST4Z_139SROVuUlxC1yxslYM2OPx-NvAF44pqjVViXGaZ4I5dPEUGuTsDibsdFGjgxecD48ktMT8e50fLoBr7q7MC0-RB9wQ8to5ms08KX1e2vQ0C9uOWRaC34NrgsZdlfoEX1cY0eloimsGl5QPF5OO1ghyvb6rlcXo188zKsOa7PiTG7B547XNtHk63BV58Pix08wjv85mNtwM3qi5HWrOndgw5V3YeswnrXfg4s23uAsKTFk-81gojtZniMBSpMsPJljVgfx4deLalaR_HtsCfOG9ziJkrN1DJLMShJhXCuC8V_8sGlL9M4K4k1dd_3jsRExfS0LEpxrEvPq54EnhAUtW5hygvDlZ5jWQxC63FX34WRy8OnNNImFHpKCa8mTwqjRyBYFYvVx6YXwNHXMq1xJYaRjY5vnqTY254WyUliqXC5EcFYsdy71BX8Am4Fj9xCIky7smHhow77aayqtFym3jOrQhw_gZSfxrIgo6FiMY561-M0sC6LIGlEM4HlPumyhP35HtNOpTRatv8oQ426k1FilA3jWvw52i4cxpnSLFdKErRznUtC_0WiNF4-ZGsB2q5I9JywsDJijFgbUKNafWcymB8fNw6N_J30KW8f7k-zD26P3j-EGQ1emyVbagc36fOV2gyNW508ag7sEObYz0A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improved+noninvasive+prediction+of+liver+fibrosis+by+liver+stiffness+measurement+in+patients+with+nonalcoholic+fatty+liver+disease+accounting+for+controlled+attenuation+parameter+values&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Petta%2C+Salvatore&rft.au=Wong%2C+Vincent+Wai-Sun&rft.au=Camma%2C+Calogero&rft.au=Hiriart%2C+Jean-Baptiste&rft.date=2017-04-01&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=65&rft.issue=4&rft.spage=1145&rft.epage=1155&rft_id=info:doi/10.1002%2Fhep.28843&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |